ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378
Ru
En

New Methods for Detecting Antiphospholipid Antibodies

DOI:10.31550/1727-2378-2019-165-10-57-62
Bibliography link: Tkachenko O.Yu., Lapin S.V., Mazing A.V., Blinova T.V., Butina S.E., Emanuel V.L. New Methods for Detecting Antiphospholipid Antibodies. Doctor.Ru. 2019; 10(165): 57–62. (in Russian) DOI: 10.31550/1727-2378-2019-165-10-57-62
New Methods for Detecting Antiphospholipid Antibodies
11 September 11:44

Objective of the Review: To describe the understanding of current methods for detecting antiphospholipid antibodies (aPL) in the blood.

Key Points: At present, in most clinical laboratories the aPL level is measured by enzyme-linked immunosorbent assay (ELISA) using special test systems, which have serious drawbacks. The advantages of new methods for detecting aPL include improved antigen sorption, automation of the procedure, and multiplexing. A chemiluminescent assay is a highly precise technology for measuring high aPL titers, achieving up to 100% sensitivity and 72.3% specificity in diagnosing antiphospholipid syndrome. Multiplex line/dot blots permit faster and more effective identification of women with all three types of aPL, and make it possible to single out those at highest risk for complications of pregnancy. They also detect antibodies to domain 1 of β2-glycoprotein I.

Conclusion: New methods for detecting aPL may improve the accuracy of diagnostics for autoimmune disorders

O.Yu. Tkachenko — Research Guidance Center for Molecular Medicine; 6-8 Lev Tolstoy St., Bldg. 28, St. Petersburg, Russian Federation 197022. eLIBRARY.RU SPIN: 6593-8770. E-mail: kachenie@mail.ru

S.V. Lapin — Research Guidance Center for Molecular Medicine; 6-8 Lev Tolstoy St., Bldg. 28, St. Petersburg, Russian Federation 197022. eLIBRARY.RU SPIN: 9852-7501. E-mail: svlapin@mail.ru

A.V. Mazing — Research Guidance Center for Molecular Medicine; 6-8 Lev Tolstoy St., Bldg. 28, St. Petersburg, Russian Federation 197022. eLIBRARY.RU SPIN: 4458-4633. E-mail: alex_mazing@mail.ru

T.V. Blinova — Research Guidance Center for Molecular Medicine; 6-8 Lev Tolstoy St., Bldg. 28, St. Petersburg, Russian Federation 197022. eLIBRARY.RU SPIN: 1637-4357. E-mail: vblinova@list.ru

S.E. Butina — Academician I.P. Pavlov First St. Petersburg State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 6-8 Lev Tolstoy St. Bldg. 28, St. Petersburg, Russian Federation 197022. E-mail: ejvcons@mail.ru

V.L. Emanuel — Research Guidance Center for Molecular Medicine; 6-8 Lev Tolstoy St., Bldg. 28, St. Petersburg, Russian Federation 197022. Academician I.P. Pavlov First St. Petersburg State Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 6-8 Lev Tolstoy St. Bldg. 28, St. Petersburg, Russian Federation 197022. eLIBRARY.RU SPIN: 1177-4802. E-mail: vladimirem1@gmail.com

New Methods for Detecting Antiphospholipid Antibodies
11 September 11:44
LITERATURE
  1. De Laat B., Derksen R.H., van Lummel M., Pennings M.T., de Groot P.G. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006; 107(5): 1916–24. DOI: 10.1182/blood-2005-05-1943
  2. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006; 4(2): 295–306. DOI: 10.1111/j.1538-7836.2006.01753.x
  3. Hoxha A., Ruffatti A., Mattia E., Meneghel L., Tonello M., Salvan E. et al. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin. Chem. Lab. Med. 2015; 53(8): 1265–70. DOI:10.1515/cclm-2014-1129
  4. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 2011; 7(6): 330–9. DOI: 10.1038/nrrheum.2011.52
  5. Inês L., Silva C., Galindo M., Lõpez-Longo F.J., Terroso G., Romão V.C. et al. Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American College of Rheumatology criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthritis Care Res. 2015; 67(8): 1180–5. DOI: 10.1002/acr.22539
  6. Mankaï A., Manoubi W., Ghozzi M., Melayah S., Sakly W., Ghedira I. High frequency of antiphospholipid antibodies in primary biliary cirrhosis. J. Clin. Lab. Anal. 2015; 29(1): 32–6. DOI: 10.1002/jcla.21723
  7. Versini M. Thyroid autoimmunity and antiphospholipid syndrome: not such a trivial association. Front. Endocrinol. (Lausanne). 2017; 8: 175. DOI: 10.3389/fendo.2017.00175
  8. Abdel-Wahab N., Talathi S., Lopez-Olivo M.A., Suarez-Almazor M.E. Risk of developing antiphospholipid syndrome following viral infection: a systematic review and meta-analysis. Lupus. 2018; 27(4): 572–83. DOI: 10.1177/0961203317731532
  9. Tincani A., Taraborelli M., Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun. Rev. 2010; 9(4): 200–2. DOI: 10.1016/j.autrev.2009.04.001
  10. Quéméneur T., Lambert M., Hachulla E., Dubucquoi S., Caron C., Fauchais A.L. et al. Significance of persistent antiphospholipid antibodies in the elderly. J. Rheumatol. 2006; 33(8): 1559–62.
  11. Meroni P.L., Chighizola C. Pathophysiology of the antiphospholipid syndrome (APS). Rev. Med. Interne. 2012; 33 (suppl. 2): A2–4. DOI: 10.1016/j.revmed.2012.09.010
  12. Mahler M., Norman G.L., Meroni P.L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun. Rev. 2012; 12(2): 313–7. DOI: 10.1016/j.autrev.2012.05.006
  13. Chighizola C.B., Pregnolato F., Andreoli L., Bodio C., Cesana L., Comerio C. et al. Beyond thrombosis: anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J. Autoimmun. 2018; 90: 76–83. DOI: 10.1016/j.jaut.2018.02.002
  14. Pengo V., Ruffatti A., Legnani C., Gresele P., Barcellona D., Erba N. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 2010; 8(2): 237–42. DOI: 10.1111/j.1538-7836.2009.03674.x
  15. Otomo K., Atsumi T., Amengual O., Fujieda Y., Kato M., Oku K. et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012; 64(2): 504–12. DOI: 10.1002/art.33340
  16. Sciascia S., Sanna G., Murru V., Roccatello D., Khamashta M.A., Bertolaccini M.L. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013; 52(8): 1397–403. DOI: 10.1093/rheumatology/kes388
  17. Devreese K.M. Antiphospholipid antibody testing and standardization. Int. J. Lab. Hematol. 2014; 36(3): 352–63. DOI: 10.1111/ijlh.12234
  18. Devreese K.M., Pierangeli S.S., de Laat B., Tripodi A., Atsumi T., Ortel T.L. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J. Thromb. Haemost. 2014; 12(5): 792–5. DOI: 10.1111/jth.12537
  19. Tkachenko O.Yu., Lapin S.V., Lazareva N.M., Shmonin A.A., Solov'eva L.N., Bondareva E.A. et al. Sravnitel'nyi analiz informativnosti test-sistem raznykh proizvoditelei dlya opredeleniya antifosfolipidnykh antitel dlya diagnostiki antifosfolipidnogo sindroma. Klinicheskaya laboratornaya diagnostika. 2017; 62(1): 40–4. (in Russian)
  20. Van Hoecke F., Persijn L., Decavele A.S., Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int. J. Lab. Hematol. 2012; 34(6): 630–40. DOI: 10.1111/j.1751-553X.2012.01448.x
  21. Capozzi A., Lococo E., Grasso M., Longo A., Garofalo T., Misasi R.et al. Detection of antiphospholipid antibodies by automated chemiluminescence assay. J. Immunol. Methods. 2012; 379(1–2): 48–52. DOI: 10.1016/j.jim.2012.02.020
  22. Noubouossie D., Valsamis J., Corazza F., Rozen L., Debaugnies F., Demulder A. An automated chemiluminescence immunoassay may detect mostly relevant IgG anticardiolipin antibodies according to revised Sydney criteria. Acta Clin. Belg. 2012; 67(3): 184–9. DOI: 10.2143/ACB.67.0.2062000
  23. Egerer K., Roggenbuck D., Büttner T., Lehmann B., Kohn A., von Landenberg P. et al. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res. Ther. 2011; 13(4): R118. DOI: 10.1186/ar3421
  24. Tkachenko O.Yu., Lapin S.V., Shmonin A.A., Solov'eva L.N., Bondareva E.A., Sel'kov S.A. i dr. Analiz spektra antifosfolipidnykh antitel u patsientov s trombozami i privychnym nevynashivaniem beremennosti Meditsinskaya immunologiya. 2018; 20(5): 753–62. (in Russian)
  25. Roggenbuck D., Borghi M.O., Somma V., Büttner T., Schierack P., Hanack K. et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res. Ther. 2016; 18(1):111. DOI: 10.1186/s13075-016-1018-x
  26. Nalli C., Somma V., Andreoli L., Büttner T., Schierack P., Mahler M. et al. Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Auto Immun. Highlights. 2018; 9(1): 6. DOI: 10.1007/s13317-018-0106-0
Similar article
19 May 15:04, Allergology
V.M. Ganuzin, N.L. Chernaya, G.S. Maskova
Features of Specialised Medical Consultation of Adolescents with Bronchial Asthma: Clinical Observation
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)
19 May 14:30, Allergology
S.E. Mitskevich, I.A. Fedorov, A.I. Chuprynina, O.G. Rybakova
Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children
Doctor.Ru Pediatrics. Vol. 19, No. 3 (2020)

Partners